The FDA has given marketing authorization to Zyn nicotine pouches. That doesn't necessarily mean they're safe to use, especially for young people, and experts say there's little evidence that they help adults quit smoking.

In a statement, the FDA said it has authorized the marketing and sale of Philip Morris International’s Zyn nicotine pouches. The pouches, which are placed between the lip and gum, are tobacco-free but contain nicotine. They come in different strengths and a variety of flavors such as citrus, coffee, peppermint and berry.

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an "extensive scientific review" about their safety.

The FDA authorized the marketing of 20 Zyn products on Thursday, marking the first allowance for the fast-growing nicotine pouches.

The FDA said "an extensive scientific review" found the products were found to pose lower risks of cancer and other serious health conditions compared to cigarettes and smokeless tobacco products.

FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products' appeal to teens.

The Food and Drug Administration (FDA) announced on Thursday that it authorized the marketing of Zyn nicotine pouches but will be "closely monitoring youth use." Newsweek reached out to Zyn for comment.

Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned 119 retailers to stop selling Zyn to underage people, and the company was ordered to pay $1.2 million last year for violating Washington, D.C.’s smokeless tobacco ban.

The U.S. Food and Drug Administration (FDA) has announced the authorization of 20 ZYN nicotine pouch products through its premarket tobacco product application (PMTA) pathway. This landmark